2020 Volume 31 Issue 3 Pages 141-152
Cyanoacrylate closure (CAC) is one of non-thermal non-tumescent treatments for varicose veins, and the VenaSeal Closure System, a commercially available CAC, was approved by national health insurance in Japan in 2019. This consensus guidelines was made by a group of experts in the field of endovenous thermal ablation for varicose veins under the auspices of the Guideline Committee of the Japanese Society of Phlebology. Symptomatic primary varicose veins are a good indication for CAC, and a history of hypersensitivity to cyanoacrylate is an absolute contraindication to CAC. Phlebitis due to delayed-type hypersensitivity or foreign body reaction is reported in 6.3% of patients as CAC specific complications. CAC is a minimally invasive method for treatment of primary varicose veins though further collection of evidence and clinical data are required to establish the long-term result.